RxDoctor Payments Data

Carol McCormick, NP

Psychiatric/Mental Health · San Marino, CANPI 1821004458

Payments from drug & device makers

$2,658in general payments, 2019–2025

Across 120 payments — averaging $22.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$481
  • Axsome Therapeutics, Inc.$221
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$220
  • Takeda Pharmaceuticals U.S.A., Inc.$210
  • Johnson & Johnson$197
  • Teva Pharmaceuticals USA, Inc.$162
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$2,63199%
  • Education$271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,658 in reported general payments places this provider in the 80th percentile of 2,433 psychiatric/mental health providers in California.

See all psychiatric/mental health providers in California

Medicare billing

Part B allowed, 2024
$66,983
Medicare patients
110
Services billed
851

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProzacFluoxetine Hcl22$11,789
TrintellixVortioxetine Hydrobromide15$10,518
PristiqDesvenlafaxine Succinate11$4,691
Escitalopram Oxalate119$2,929
Lisdexamfetamine Dimesylate17$2,646
Duloxetine Hcl106$2,619
Bupropion XlBupropion Hcl77$2,462
Vilazodone Hcl24$2,314
Fluoxetine Hcl59$1,518
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine42$1,456
Aripiprazole31$1,152
Mirtazapine36$1,010
Trazodone Hcl85$964
Sertraline Hcl78$904
Quetiapine Fumarate42$752

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$210$10,51815 claims
Almatica Pharma LLCSertraline Hcl$99$90478 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,433 psychiatric/mental health providers in California.

Other psychiatric/mental health in San Marino

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →